Alltrna
MA - CambridgeBiotechnology
Focus: Alltrna is a Cambridge-based biotechnology company pioneering tRNA therapies, a novel disease-agnostic genetic medicine platform founded in 2014 and now publicly traded. The company is in early clinical development with its first tRNA therapy approaching or entering clinical trials.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$6B
Open Jobs
2+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Alltrna?
AI assessmentHigh-risk, high-reward early-stage bet suitable only for scientists and operators willing to tolerate organizational instability in exchange for exposure to novel biology.
Why Work Here
- First-mover advantage in an entirely new therapeutic modality (tRNA therapies) with potential across multiple disease areas
- Pioneering clinical-stage science: company is nearing or entering first human trial of tRNA therapy, offering rare ground-floor opportunity in emerging platform
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alltrna
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.